Tools for Practice Outils pour la pratique

#153 Ginger for Nausea and Vomiting of Pregnancy: A queasy question

Is ginger an option for nausea and vomiting of pregnancy?

In the first trimester, at best, ginger may improve nausea and vomiting ~on a 40 point-scale or stop vomiting for one in three women at six days. Safety in the largest cohort study suggests no increase in fetal malformations or stillbirths, although smaller studies found trends suggesting otherwise. 

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

  • Seven systematic reviews of Randomized Controlled Trials (RCTs) with similar results.1-7   
    • Focusing on the Cochrane review, statistically significant results in:1   
      • At best, mean difference in 40-point nausea and vomiting scale was 4.19 over placebo at one week (one RCT, 70 women).   
      • Still vomiting at day six: 33.3% (ginger) versus 80% (placebo), Number Needed to Treat (NNT)=3 (one RCT, 22 women). 
      • Adverse effects rarely reported but no differences in spontaneous abortion or c-section rates (one RCT, 67 women), or congenital abnormalities (one RCT, 120 women). 
      • No difference versus vitamin B6 (four RCTs, 625 women)metoclopramide (one RCT, 68 women), or doxylamine/pyridoxine (one RCT, 63 women).   
      • Limitations: Short-term, adverse effects rarely reported, inconsistent outcome measurements, studies underpowered.2 
    • Cohort safety studies (mostly first or second trimester): 
      • 68,522 women (1,020 used ginger): No increase in fetal malformations, stillbirth/neonatal death, or preterm birth.8   
        • Vaginal bleeding/spotting after 17 weeks significantly increased (7.8% versus 5.8%). Nosignificant for heavier “bleeding” (spotting excluded) and no differences in bleeding-related hospitalization.  
      • 375 women: No increased major malformations, stillbirths, spontaneous abortion. More small babies (<2500 g) in the control group (1.6% versus 6.4%).9   
      • 441 women: No difference in spontaneous abortion, but trend (p-values ~0.05) toward increased stillbirths (2.7% versus 0.3%) and major malformations (3.3% versus 0.7%).10  
        • Limitations: Small numbers, short exposure (median two days), and wide confidence intervals. 
  • Based on limited clinical evidence, ginger is considered contraindicated close to labour or if history of miscarriage, vaginal bleeding, or clotting disorders due to potential hemorrhage. Also concerns exist about potential to bind testosterone receptors.8  
  • Dose is usually ~1 g/day, divided BID to QID.1   
  • Evidence inconsistent for use in motion sickness,11,12 post-operative nausea/vomiting,13-16 and chemotherapy-induced nausea/vomiting.17,18  

Latest Tools for Practice
Derniers outils pour la pratique

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • Adrienne J Lindblad BSP ACPR PharmD
  • Sudha Koppula MD MCISc CCFP

1. Matthews A, Haas DM, O’Mathúna DP, et al. Cochrane Database Syst Rev. 2014; 3:CD007575.

2. Festin M. BMJ Clin Evid. 2014 Mar 19; 2014.

3. Thomson M, Corbin R, Leung L. J Am Board Fam Med. 2014; 27:115-22.

4. Ding M, Leach M, Bradley H. Women Birth. 2013; 26(1):e26-30.

5. Dante G, Pedrielli G, Annessi E, et al. J Matern Fetal Neonatal Med. 2013; 26(3):306-12.

6. ViljoenE, Visser J, Koen N, et al. Nutr J. 2014; 13:20.

7. Borelli F, Capasso R, Aviello G, et al. Obstet Gyencol. 2005; 105:849-56.

8. Heitmann K, Nordeng H, Holst L. Eur J Clin Pharmacol. 2013; 69:269-77.

9. Portnoi G, Chng LA, Karimi-Tabesh L, et al. Am J Obstet Gynecol. 2003; 189(5):1374-7.

10. Choi JS, Han JY, Ahn HK, et al. J Obstet Gynaecol. 2015; 35:125-30.

11. Grøntved A, Brask T, Kambskard J, et al. Acta Otolaryngol. 1988; 105(1-2):45-9.

12. Schmid R, Schick T, Steffen R, et al. J Travel Med. 1994 Dec 1; 1(4):203-6.

13. Carlisle J, Stevenson CA. Cochrane Database Syst Rev. 2006; 3:CD004125.

14. Chaiyakunapruk N, Kitikannakorn N, Nathisuwan S, et al. Am J Obstet Gynecol. 2006; 194:95-9.

15. Montazeri AS, Hamidzadeh A, Raei M, et al. Iran Red Crescent Med J. 2013; 15(12):e12268.

16. Kalava A, Darji SJ, Kalstein A, et al. Eur J Obstet Gynecol Reprod Biol. 2013; 169:184-8.

17. Lee J, Oh H. Oncol Nurs Forum. 2013 Mar; 40(2):163-70.

18. Marx WM, Teleni L, McCarthy AL, et al. Nutr Rev. 2013; 71:245-54.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.